Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Randomized Trial Evaluting Aflibercept Associated With LV5FU2 Regimen as First Line Treatment of Non-resectalbe Metastatic Colorectal Cancers

Next Previous
Trial Profile

Phase II Randomized Trial Evaluting Aflibercept Associated With LV5FU2 Regimen as First Line Treatment of Non-resectalbe Metastatic Colorectal Cancers

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 18 Sep 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Aflibercept (Primary) ; Fluorouracil; Folinic acid
  • Indications Adenocarcinoma; Colon cancer; Colorectal cancer; Rectal cancer
  • Focus Therapeutic Use
  • Acronyms FOLFA

Most Recent Events

  • 07 Jun 2022 Primary endpoint (Radiological progression-free survival according to the investigator) has been met, according to Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology.
  • 07 Jun 2022 Results assessing ial safety and efficacy of aflibercept and infusional 5-fluorouracil/folinic acid combination versus LV5FU2 alone in older patients,presented at the 58th Annual Meeting of the American Society of Clinical Oncology.
  • 23 Mar 2022 Status changed from recruiting to completed.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top